Vergallo, A;
Lista, S;
Lemercier, P;
Chiesa, PA;
Zetterberg, H;
Blennow, K;
Potier, M-C;
... Alzheimer Precision Medicine Initiative (APMI); + view all
(2020)
Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers.
Neurobiology of Aging
, 96
pp. 22-32.
10.1016/j.neurobiolaging.2020.07.009.
Preview |
Text
Zetterberg_Vergallo.pdf - Accepted Version Download (490kB) | Preview |
Abstract
Neuroinflammation, a key early pathomechanistic alteration of Alzheimer's disease, may represent either a detrimental or a compensatory mechanism or both (according to the disease stage). YKL-40, a glycoprotein highly expressed in differentiated glial cells, is a candidate biomarker for in vivo tracking neuroinflammation in humans. We performed a longitudinal study in a monocentric cohort of cognitively healthy individuals at risk for Alzheimer's disease exploring whether age, sex, and the apolipoprotein E ε4 allele affect plasma YKL-40 concentrations. We investigated whether YKL-40 is associated with brain amyloid-β (Aβ) deposition, neuronal activity, and neurodegeneration as assessed via neuroimaging biomarkers. Finally, we investigated whether YKL-40 may predict cognitive performance. We found an age-associated increase of YKL-40 and observed that men display higher concentrations than women, indicating a potential sexual dimorphism. Moreover, YKL-40 was positively associated with memory performance and negatively associated with brain Aβ deposition (but not with metabolic signal). Consistent with translational studies, our results suggest a potentially protective effect of glia on incipient brain Aβ accumulation and neuronal homeostasis.
Archive Staff Only
 |
View Item |
